With ~¥100M Series B, ForeFront Pharma accelerates global push for PAH drug treprostinil

Recently, ForeFront Pharma, a company dedicated to drug R&D for global rare diseases, successfully completed a Series B financing round raising nearly 100 million RMB. WeVest Partners served as the company's long-term exclusive financial advisor.

This round of financing saw participation from five institutions, including Grand Pharmaceutical Group, Shenzhen Credit Guarantee Group Venture Capital, and Chisage Capital. Concurrently, ForeFront Pharma entered into a CSO (Contract Sales Organization) collaboration with Grand Pharmaceutical for the company's core product series of treprostinil, which is used to treat pulmonary arterial hypertension (PAH), aiming to jointly advance the market commercialization of this product series. Currently, this product series has achieved outstanding progress in commercialization.

The proceeds from this financing round will be primarily allocated towards: 1) Accelerating the market approval and commercial launch of the core treprostinil product series and other rare disease therapies in China and overseas; 2) Advancing the clinical research and/or bioequivalence evaluation of the company's other innovative pipeline candidates; and 3) Optimizing R&D facilities, equipment, and personnel.

Dr. Yi Ren, Founder of ForeFront Pharma, stated: "We are greatly honored to receive the recognition and support from Grand Pharmaceutical, Shenzhen Credit Guarantee Group Venture Capital, and Chisage Capital. The completion of this financing round not only affirms ForeFront Pharma's R&D capabilities and product value but also injects robust momentum into the company's next phase of development. The CSO collaboration with Grand Pharmaceutical will significantly accelerate the commercialization of our core products, enabling our innovative achievements to benefit patients more swiftly."